Email Alert Sign Up Confirmation- Privacy Notice
- McKesson.com
- Cookie Settings
- Asia Pacific
- Latin America
- Middle East & Africa
- North America
- Australia & New Zealand
Mainland China - Hong Kong SAR, China
- Philippines
- Taiwan, China
- Channel Islands
- Netherlands
- Switzerland
- United Kingdom
- Saudi Arabia
- South Africa
- United Arab Emirates
- United States
From startups to legacy brands, you're making your mark. We're here to help. - Innovation Economy Fueling the success of early-stage startups, venture-backed and high-growth companies.
- Midsize Businesses Keep your company growing with custom banking solutions for middle market businesses and specialized industries.
- Large Corporations Innovative banking solutions tailored to corporations and specialized industries.
- Commercial Real Estate Capitalize on opportunities and prepare for challenges throughout the real estate cycle.
- Community Impact Banking When our communities succeed, we all succeed. Local businesses, organizations and community institutions need capital, expertise and connections to thrive.
- International Banking Power your business' global growth and operations at every stage.
- Client Stories
Prepare for future growth with customized loan services, succession planning and capital for business equipment. - Asset Based Lending Enhance your liquidity and gain the flexibility to capitalize on growth opportunities.
- Equipment Financing Maximize working capital with flexible equipment and technology financing.
- Trade & Working Capital Experience our market-leading supply chain finance solutions that help buyers and suppliers meet their working capital, risk mitigation and cash flow objectives.
- Syndicated Financing Leverage customized loan syndication services from a dedicated resource.
- Employee Stock Ownership Plans Plan for your business’s future—and your employees’ futures too—with objective advice and financing.
Institutional Investing Serving the world's largest corporate clients and institutional investors, we support the entire investment cycle with market-leading research, analytics, execution and investor services. - Institutional Investors We put our long-tenured investment teams on the line to earn the trust of institutional investors.
- Markets Direct access to market leading liquidity harnessed through world-class research, tools, data and analytics.
- Prime Services Helping hedge funds, asset managers and institutional investors meet the demands of a rapidly evolving market.
- Global Research Leveraging cutting-edge technology and innovative tools to bring clients industry-leading analysis and investment advice.
- Securities Services Helping institutional investors, traditional and alternative asset and fund managers, broker dealers and equity issuers meet the demands of changing markets.
- Financial Professionals
- Liquidity Investors
Providing investment banking solutions, including mergers and acquisitions, capital raising and risk management, for a broad range of corporations, institutions and governments. - Center for Carbon Transition J.P. Morgan’s center of excellence that provides clients the data and firmwide expertise needed to navigate the challenges of transitioning to a low-carbon future.
- Corporate Finance Advisory Corporate Finance Advisory (“CFA”) is a global, multi-disciplinary solutions team specializing in structured M&A and capital markets. Learn more.
- Development Finance Institution Financing opportunities with anticipated development impact in emerging economies.
- Sustainable Solutions Offering ESG-related advisory and coordinating the firm's EMEA coverage of clients in emerging green economy sectors.
- Mergers and Acquisitions Bespoke M&A solutions on a global scale.
- Capital Markets Holistic coverage across capital markets.
- Capital Connect
In Context Newsletter from J.P. Morgan- Director Advisory Services
Accept PaymentsExplore blockchain, client service, process payments, manage funds, safeguard information, banking-as-a-service, send payments. A uniquely elevated private banking experience shaped around you. - Banking We have extensive personal and business banking resources that are fine-tuned to your specific needs.
- Investing We deliver tailored investing guidance and access to unique investment opportunities from world-class specialists.
- Lending We take a strategic approach to lending, working with you to craft the fight financing solutions matched to your goals.
- Planning No matter where you are in your life, or how complex your needs might be, we’re ready to provide a tailored approach to helping your reach your goals.
Whether you want to invest on your own or work with an advisor to design a personalized investment strategy, we have opportunities for every investor. - Invest on your own Unlimited $0 commission-free online stock, ETF and options trades with access to powerful tools to research, trade and manage your investments.
- Work with our advisors When you work with our advisors, you'll get a personalized financial strategy and investment portfolio built around your unique goals-backed by our industry-leading expertise.
- Expertise for Substantial Wealth Our Wealth Advisors & Wealth Partners leverage their experience and robust firm resources to deliver highly-personalized, comprehensive solutions across Banking, Lending, Investing, and Wealth Planning.
- Why Wealth Management?
- Retirement Calculators
- Market Commentary
Who We Serve INDUSTRIES WE SERVEExplore a variety of insights. Global ResearchInsights by Topic Explore a variety of insights organized by different topics. Insights by Type Explore a variety of insights organized by different types of content and media. We aim to be the most respected financial services firm in the world, serving corporations and individuals in more than 100 countries. - Commercial & Investment Banking by Industry Expertise
- Health Care
- J.P. Morgan Healthcare Conference: Deals and Medical Moonshots
J.P. Morgan Healthcare Conference: Deals and medical moonshotsHighlights from the 41st annual J.P. Morgan Healthcare Conference, the industry’s biggest gathering. February 10, 2023 The health care industry was under the microscope recently as J.P. Morgan staged its 41st annual Healthcare Conference in San Francisco from January 9-12, 2023—back in person again for the first time in three years. The Conference is the industry’s biggest gathering, bringing together more than 8,000 investors, industry professionals, senior government officials and 550 global health care companies—ranging from Fortune 100 corporations to small-cap and emerging private companies—to discuss the latest market trends and medical innovations. Breakthrough drugsEvery year, the event brings news and updates on new drugs and breakthrough treatments. This year, pioneering drugs for Alzheimer’s and diabetes grabbed headlines. A new class of medicines has started to come to market to prevent the onset of diabetes and combat obesity, thereby lowering the risk of heart attacks and stroke, the audience heard. Companies including Eli Lilly, Amgen, Pfizer and Regeneron are fighting to develop medications in a market estimated to be worth more than $30 billion per year. Elsewhere, Biogen CEO Chris Viehbacher discussed his company’s new Alzheimer’s drug lecanemab, developed with Japanese partner Eisai, which recently received the green light from the Food and Drug Administration. The FDA’s approval comes after clinical trial results published in November 2022 indicated that lecanemab slows cognitive decline in people with mild forms of Alzheimer’s. Currently, people with Alzheimer’s are given other drugs to help manage their symptoms, but none change the course of the disease. Lecanemab is a breakthrough drug and offers hope to many people, said Viehbacher. But along with the job of marketing the drug, it is critical to educate the public about Alzheimer’s, he stressed. “People think Alzheimer’s is a little bit of memory loss and don’t fully understand that this is a fatal disease.” Birthplace of dealsThe Conference is also the birthplace of a lot of deals, with companies announcing major transactions in the run-up. Building off the momentum at the end of 2022, when J.P. Morgan's Global Head of Health Care Investment Banking, Mike Gaito, and his team led the industry’s biggest merger—the $28 billion sale of Horizon Therapeutics to Amgen—more than $3.5 billion worth of deals were announced to coincide with the Conference. Chiesi’s $1.25 billion acquisition of rare disease drugmaker Amryt Pharma and AstraZeneca’s $1.3 billion buyout of CinCor Pharma, which gives it access hypertension and kidney disease treatments, were among the highlights. These biotech buyouts gave the Conference a jumpstart, suggesting that the uptick in M&A activity that began in the second half of last year could stick around. investment-banking/mergers-and-acquisitions-market-outlook The M&A environment should “be really vibrant in 2023,” said Gaito, who opened the conference.  Mike Gaito speaks at the 41st annual J.P. Morgan Healthcare Conference. (Photo credit: Lucy Kennedy Photography) “We’ll continue to see growth acquisitions across all parts of the industry. There’s a drive for growth right now and there’s a recognition that we’ve had a valuation reset over the last 12 to 18 months so that makes the buyers even more aggressive and even more interested,” he told Bloomberg. In late 2022, J.P. Morgan also led the $6 billion sale of Nimus to Takeda, as well as advised Johnson and Johnson on its $17 billion acquisition of medical devices company Abiomed. Many big pharma companies are seeking to replenish revenues as their top-selling drugs reach the end of patent protection, sparking fierce competition for new medicines and a flurry of deals, especially with biotech firms. The convergence of health care and technology is also driving deal activity, Gaito added, “whether it’s AI and machine learning for drug discovery, or the same for diagnostic discovery, or new technologies brought into the health care services realm for patient care in the digital health world.” Health of the economyOther sessions explored the broader economic and geopolitical environment. In press interviews and his keynote address, Chairman and CEO Jamie Dimon shared his outlook on inflation, Fed policy and the health of the U.S. consumer amid looming recession fears .  Jamie Dimon and Mike Gaito in conversation at the 41st annual J.P. Morgan Healthcare Conference. (Photo credit: Lucy Kennedy Photography) “The consumer is still strong,” Dimon told Fox Business. “Their balance sheets are in good shape. They’re spending 10% more than pre-Covid. They have more in their checking account, companies are in good shape and that’s driving a strong economy.” On the outlook for J.P. Morgan, he noted: “We have a lot of growth plans” and continue to invest through all economic cycles. “I tend not to stop growing because of a recession. Even in a recession, we’re opening in new countries,” he said, highlighting the overall resiliency of the U.S. economy and the financial system. Related insights Healthcare ConferenceHighlights from the annual J.P. Morgan Healthcare Conference, the industry’s biggest gathering.  Sign up for the bi-weekly In Context newsletter, bringing market views and industry news from J.P. Morgan straight to your inbox.  Leveraging cutting-edge technology and innovative tools to bring clients industry-leading analysis and investment advice. For Corporate Clients only – This material (including market commentary, market data, observations or the like) has been prepared by personnel in the Healthcare Group of JPMorgan Chase & Co. and/or its affiliates (collectively, “J.P Morgan”). It has not been reviewed, endorsed or otherwise approved by, and is not a work product of, any research department of J.P. Morgan. This material is intended merely to highlight market developments and is not intended to be comprehensive and does not constitute investment, legal or tax advice, nor does it constitute an offer or solicitation for the purchase or sale of any financial instrument or a recommendation for any investment product or strategy. RESTRICTED DISTRIBUTION: This material is distributed by the relevant J.P. Morgan entities that possess the necessary licenses to distribute the material in the respective countries. This material is proprietary and confidential to J.P. Morgan and is for your personal use only. Any distribution, copy, reprints and/or forward to others without permission from, or attribution to, J.P. Morgan is strictly prohibited. Copyright JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A., organized under the laws of U.S.A. with limited liability. You're now leaving J.P. Morgan J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name. J.P. Morgan 39th Annual Healthcare Conference- Add to Apple Calendar
- Add to Google Calendar
- Add to Microsoft Outlook
- Add to iCalendar
Teladoc Health Investor Presentation - January 2021- View this Presentation ( PDF )
 Investor RelationsGet in touch today. Contact Teladoc Health Investor Relations Patrick Feeley Vice President, Investor Relations (914) 265-7925 Michael Minchak | Vice President, Investor Relations | [email protected] [email protected] [email protected]  - Web and Mobile Privacy Policy
- Web and Mobile Terms & Conditions
- Notice of Privacy Practices
- Notice of Non-Discrimination
 39th Annual J.P. Morgan Healthcare ConferenceJanuary 11, 2021 02:00 PM ET +1 (510) 474-0170 [email protected] Stay ConnectedGet our news and updates delivered to your inbox:. Privacy Policy | Terms of Use | © 2024 Protagonist Therapeutics Inc. All Rights Reserved. Health Equity: Improving Access to Medicines, Ensuring Diverse RepresentationSpotlight, Arturo Molina, MD, Chief Medical Officer  Dr. Molina, how are you helping to advance access to medicines?At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude. We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data. We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials. Protagonist: Inclusion by the NumbersSpotlight: Carena Spivey, Head of HR Carena, equality, inclusion, and workplace diversity have long been in focus at Protagonist, as expressed through various programs and initiatives. Can you tell us about your approach?We view our diverse and welcoming corporate culture as being critical to our long-term success – It’s essential to the way we innovate. And we regularly track and report our progress, because we believe that what doesn’t get measured doesn’t get done. Today: - 65% of employees are members of underrepresented ethnic communities - 51% are women - nearly 50% of our Board identifies as a member of an underserved community or as female What are you doing to help create a more diverse employee community?We create the conditions for our employees to thrive, facilitating their learning and growth through a richly supportive workplace setting. Part of that is creating a speak-up culture; we have cultivated an environment where every voice is heard, and we encourage the expression of different points of view in decision-making processes. At every turn, we encourage deep listening, thoughtful consideration, and open-mindedness that allows for decisions to be changed or refined in step with new data. By embracing our team members’ differences, we create wins for our organization and for patients. How we do businessAwards and recognition.  Chairman and CEO Letter to Shareholders Annual Report 2023 CommitmentsDiversity, equity and inclusion. Latest news  An Ohio-based company is protecting first responders around the world With support from JPMorganChase, Fire-Dex is providing protective equipment to firefighters in 100 countries and all 50 states. Explore all topics How vulnerable are Americans to unexpected expenses? JPMorgan Chase Institute Work with usGrow with us, how we hire, explore opportunities, students and graduates.  Veteran’s Unconventional Path to Landing her Dream Job in Tech U.S. Army Veteran Ashley Wigfall transitioned to a civilian role and charted her path to technologist through mentorship and skills training at the JPMorgan Chase tech hub in Plano, Texas. Investor Relations Events & PresentationsUpcoming events, past events. Type Of Event Sign up for Investor news and alertsSign up for updates on the ways we are using our expertise, data, resources and scale to open new pathways to economic opportunity and drive inclusive growth in communities around the world. Contact InformationFor help as a customer or client:. - For help with your Chase account
- For Chase customer complaints and feedback
- For help with J.P. Morgan Securities wealth management accounts
- For questions on Asset Management, including Fund details
- For general inquiries regarding JPMorgan Chase & Co. or other lines of business or call 212-270-6000
For shareholder and fixed income assistance, including requests for printed materials, please contactInvestor Relations JPMorgan Chase & Co. 277 Park Avenue New York, NY 10172-0003 212-270-2479 [email protected] For ADA-related inquiries, please contact [email protected] with the subject line “ADA inquiry” Stock Trade InformationStock transfer agent:, computershare, by regular mail computershare po box 43006 providence, ri 02940-3006, by overnight delivery: computershare 150 royall street suite 101 canton, ma 02021 800-758-4651 (toll free) 201-680-6862 (international) www.computershare.com, you are now leaving jpmorganchase. JPMorganChase's website terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its website terms, privacy and security policies to see how they apply to you. JPMorganChase isn't responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the JPMorganChase name. Your browser is out of date With an updated browser, you will have a better Medtronic website experience. Update my browser now.  Medtronic CEO, Geoff Martha Speaks at the JP Morgan Healthcare Conference from Medtronic on Vimeo .  Event Details39th annual j.p. morgan healthcare conference, speaker(s):. - Jeffrey Simmons President and Chief Executive Officer
- Add to Apple Calendar
- Add to Google Calendar
- Add to Microsoft Outlook
- Add to iCalendar
- Presentation (opens in new window) PDF 1.42 MB
About Elanco Learn why we're a leading provider of innovative solutions that protect and enhance animal health. Our Company- We Are Elanco
- Our Journey
- Elanco Healthy Purpose
Our ExpertiseWhats happening. Join Elanco- Joining the Team
- Graduate Program
- Why Work For Elanco
- Wellbeing & Benefits
Invest in Elanco- Why Invest?
- Stock Information
- Financials & Filings
- Investor Resources
Connect with Elanco- Privacy Statement
- Terms of Use
- Safety Data Sheets
- Newly Aquired Safety Data Sheets
Event DetailsJ.p. morgan healthcare conference presentation & breakout session. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. | * | Email Alert Sign Up ConfirmationGeneral Inquiries Salli Schwartz, Vice President lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122 858.291.6421 [email protected] Transfer Agent Computershare Trust Company, N.A. Courier Delivery: P.O. Box 43006 Providence RI 02940-3006 Overnight Delivery: 150 Royall St. STE 101 Canton, MA 02021 877.373.6374 www.computershare.com Tools & Links- Latest Presentation
- SEC Filings
- Q1’21 Earnings Results
Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. For Research Use Only. Not for use in diagnostic procedures (except as specifically noted). © Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html . | | 
IMAGES
COMMENTS
On January 6, 2021, R1 announced that it has entered into an agreement for the conversion of preferred stock held by Ascension and TowerBrook to common stock. As part of the agreement, the holders will receive: 139.3 million common shares. A one-time cash payment of $105 million, funded with cash from balance sheet.
1. Executing on strategy to. provide differentiated value to healthcare providers through technology-enabled, end-to-end supply chain and enterprise analytics and performance improvement solutions to help drive improved health outcomes and reduce costs. 2. Generate strong free cash flow and maintain.
January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference. 2 IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue ... 2021 (4) As of January 8, 2021; (5) As of December 31, 2020; (6) Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates.
The 42nd Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA. This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Wednesday, January 13, 2021 J.P. Morgan Healthcare Conference 2021. Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as ...
J.P. Morgan Healthcare Conference. Clay Siegall, Ph.D. President and Chief Executive Officer. January 11, 2021. Forward-Looking Statements. 2. Certain of the statements made in this presentation are forward looking, such as those, among others, relating to the Company's potential to achieve the
Presentation | JP Morgan Healthcare Conference 2021. Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our R&D and clinical pipeline, our expectations ... ~€50M,""Jyseleca in Europe,"and "Newsflow 2021," statements regarding the expected timing ...
39th Annual J.P. Morgan Healthcare Conference. January 11, 2021 4:30 PM ET. 39TH Annual J.P. Morgan Healthcare Conference Presentation.
DIGITAL HEALTH PIONEERS FORUM. 12:00 - 12:10 pm WELCOME AND OPENING REMARKS. 12:40 pmTHE FUTURE OF IT IN HEALTHCAREAfter 27 years with Microsoft, BJ Moore made the move to executive vice president and chief information oficer of. 51-hospital system spanning six states. Three years later, the expansive system focuses on connectivity, in.
J.P. Morgan 39th Annual Healthcare Conference Francis deSouza President & Chief Executive Officer. January 11, 2021 . Cautionary Notes on Forward-Looking Statements. This presentation contains "forward- looking statements "within the meaning of the federal securities laws, including Section27A of the ...
This presentation contains forward-looking statements that are based on our management's beliefs and assumptions and ... 7 J.P. Morgan Healthcare Conference | January 12, 2021. PIPER Living with Dravet syndrome Epidiolex® ... Epidiolex 2021: Building a Blockbuster 14 J.P. Morgan Healthcare Conference | January 12, 2021 BUILD Build on positive
39th Annual J.P. Morgan Healthcare Conference: Presentation and Q&A. January 12, 2021 9:10 AM ET. Webcast (opens in new window) Presentation (opens in new window) Contact Us. Send Email. Investor Email Alerts.
Bayer. Bayer presentation delivered at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 AM. [music] Richard Vosser: Good morning, good afternoon. Welcome to the third day of the 39th J.P. Morgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst at J.P. Morgan.
39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. 2 Provided January 11, 2021, as part of an oral presentation and is qualified ... Provided January 11, 2021, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary
February 10, 2023. The health care industry was under the microscope recently as J.P. Morgan staged its 41st annual Healthcare Conference in San Francisco from January 9-12, 2023—back in person again for the first time in three years.. The Conference is the industry's biggest gathering, bringing together more than 8,000 investors, industry professionals, senior government officials and 550 ...
J.P. Morgan 39th Annual Healthcare Conference. January 11, 2021 10:00 AM EST. View Webcast. Add to Apple Calendar; ... Add to Microsoft Outlook; Add to iCalendar; Teladoc Health Investor Presentation - January 2021. View this Presentation ( PDF) Investor Relations. NYSE: TDOC. 7.11
39th Annual J.P. Morgan Healthcare Conference. January 11, 2021 02:00 PM ET. VIEW WEBCAST. DOWNLOAD PRESENTATION. Contact Us +1 (510) 474-0170 [email protected] Stay Connected. Innovation. Community. Leadership. Investors. News. Careers. Get Our News And Updates Delivered To Your Inbox:
JPMorganChase Fourth-Quarter 2024 Earnings Conference Call Jan 15, 2025.
Past Events & Presentations; General Manager Call Series; Dividends ... J.P. Morgan Healthcare Conference Monday, January 11, 2021 8:20am EST. Medtronic CEO, Geoff Martha Speaks at the JP Morgan Healthcare Conference from Medtronic on Vimeo. JP Morgan Healthcare Conference Handout. 2.5 MB.
1Adjusted for share split, which has been effective since June 30, 2014; 2Final decision is subject to Annual General Meeting approval; 3Calculated with 2019 year-end share price of € 105.35 per share. China's VBP: Round 3 completed, sustained confidence in keeping base business at least stable until 2022.
Bristol Myers Squibb is a leading Biopharma company focused on Innovation and well positioned for growth. Established a strong foundation in 2020. Leading in-line medicines, significant short term launch opportunities, and a rich pipeline in each therapeutic area of focus. Expect to deliver low to mid-single digit revenue CAGR from 2020 to 2025.
Event Details. Home Events & Presentations > Event Details. January 12, 2021 07:30 AM ET.
General Inquiries. Salli Schwartz, Vice President lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. 858.291.6421 [email protected]